Learn More
Invitrogen™ NFkB p50 Monoclonal Antibody (5D10D11)

Description
MA5-15870 targets NFKB1 in FACS, IF, IHC, ChIP, and WB applications and shows reactivity with Human samples.
Specifications
Specifications
| Antigen | NFkB p50 |
| Applications | ChIP Assay, Flow Cytometry, Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry |
| Classification | Monoclonal |
| Clone | 5D10D11 |
| Concentration | 1 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 0.05% sodium azide |
| Gene | NFKB1 |
| Gene Accession No. | P19838 |
| Gene Alias | CVID12; DKFZp686C01211; DNA-binding factor KBF1; EBP-1; KBF1; MGC54151; NF kappaB1; NF KB; NFkappaB; NF-kappaB; NF-kappa-B; NF-kappaB p50; NF-kappaB1; NF-kappa-B1 p84/NF-kappa-B1 p98; NF-kappabeta; NF-kB; NF-kB p50; NFKB1; NF-kB1; NFKB-p105; NFKB-p50; nuclear factor; nuclear factor kappa b; nuclear factor kappa B subunit 1; nuclear factor kappa-B 1; nuclear factor kappa-B DNA binding subunit; nuclear factor kappaB p50; nuclear factor NF-kappa-B p105 subunit; nuclear factor NF-kappa-B p105 subunit-like protein; nuclear factor NF-kappa-B p50 subunit; nuclear factor of kappa light chain gene enhancer in B-cells 1, p105; nuclear factor of kappa light polypeptide enhancer in B-cells 1; nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105; nuclear factor of kappa light polypeptide gene enhancer in B-cells 1; nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105); nuclear factor of kappa light polypeptide gene enhancer in B-cells 1, p105; nuclear factor-kappaB p50; OTTHUMP00000219572; p105; p50; p50 subunit of NF kappaB; p50 subunit of NF-kappaB; p50/p105; RHD of nuclear factor NF-kappa-B p105 subunit |
| Show More |
Safety and Handling
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.